Company intelligence / Profile preview
EPIRUS Biopharmaceuticals, Inc.
Boston, Massachusetts, USAepirusbiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EPIRUS developed a pipeline of biosimilar monoclonal antibodies targeting blockbuster biologics. Its lead asset BOW015 was an infliximab biosimilar in global Phase III studies. Other programs were at preclinical or early clinical stages. The company reprioritized its pipeline in later years to focus on rare diseases but did not reach commercialization before ceasing operations.
- Therapeutic areas
- HematologyImmunology
- Modalities
- monoclonal antibodies (mAbs)biosimilars
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Multiple partnerships for regulatory/commercialization efforts globally; specifics not detailed in available sources
Beyond the preview
Go deeper on EPIRUS Biopharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPIRUS Biopharmaceuticals, Inc..